Ruben G.W. Quek
About
Ruben G.W. Quek is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics.
According to data from OpenAlex, Ruben G.W. Quek has authored 80 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 23 papers in Economics and Econometrics. Recurrent topics in Ruben G.W. Quek's work include PARP inhibition in cancer therapy (20 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers) and Lung Cancer Treatments and Mutations (18 papers). Ruben G.W. Quek is often cited by papers focused on PARP inhibition in cancer therapy (20 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers) and Lung Cancer Treatments and Mutations (18 papers). Ruben G.W. Quek collaborates with scholars based in United States, United Kingdom and France. Ruben G.W. Quek's co-authors include Anthony Gonçalvès, Hope S. Rugo, Sara A. Hurvitz, Johannes Ettl, Joanne L. Blum, Jennifer K. Litton, Lida A. Mina, W. Eiermann, Miguel Martín and Young‐Hyuck Im and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Ruben G.W. Quek
72 papers receiving 3.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ruben G.W. Quek United States | 20 | 1.8k | 939 | 916 | 767 | 683 | 80 | 3.0k | ||
| Peter Barrett‐Lee United Kingdom | 35 | 2.6k 1.4× | 885 0.9× | 671 0.7× | 586 0.8× | 1.4k 2.0× | 121 | 5.0k | ||
| Erica L. Mayer United States | 31 | 2.6k 1.4× | 1.4k 1.5× | 997 1.1× | 495 0.6× | 1.2k 1.8× | 144 | 4.7k | ||
| José Bines Brazil | 22 | 2.7k 1.5× | 549 0.6× | 1.0k 1.1× | 694 0.9× | 1.4k 2.0× | 94 | 3.7k | ||
| Marc Debled France | 30 | 1.9k 1.1× | 716 0.8× | 1.1k 1.2× | 635 0.8× | 1.5k 2.2× | 121 | 3.8k | ||
| Wenting Wu China | 9 | 2.7k 1.5× | 1.5k 1.6× | 1.8k 1.9× | 842 1.1× | 1.0k 1.5× | 23 | 4.0k | ||
| Agustí Barnadas Spain | 34 | 2.0k 1.1× | 1.6k 1.7× | 789 0.9× | 383 0.5× | 1.2k 1.8× | 141 | 4.1k | ||
| Shannon N. Westin United States | 39 | 1.8k 1.0× | 1.5k 1.6× | 608 0.7× | 462 0.6× | 825 1.2× | 276 | 5.4k | ||
| T. Delozier France | 30 | 3.3k 1.8× | 568 0.6× | 987 1.1× | 468 0.6× | 1.7k 2.4× | 92 | 4.3k | ||
| Alistair Ring United Kingdom | 25 | 1.4k 0.8× | 556 0.6× | 557 0.6× | 397 0.5× | 1.1k 1.6× | 108 | 2.5k | ||
| Masashi Ando Japan | 31 | 2.0k 1.1× | 688 0.7× | 954 1.0× | 153 0.2× | 774 1.1× | 206 | 3.6k |
Countries citing papers authored by Ruben G.W. Quek
Since
Specialization
Citations
This map shows the geographic impact of Ruben G.W. Quek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruben G.W. Quek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruben G.W. Quek more than expected).
Fields of papers citing papers by Ruben G.W. Quek
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ruben G.W. Quek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruben G.W. Quek. The network helps show where Ruben G.W. Quek may publish in the future.
Co-authorship network of co-authors of Ruben G.W. Quek
This figure shows the co-authorship network connecting the top 25 collaborators of Ruben G.W. Quek. A scholar is included among the top collaborators of Ruben G.W. Quek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruben G.W. Quek. Ruben G.W. Quek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Park, Soo Jung, David M. Ellison, Ryan Weight, et al.. (2025). CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. Future Oncology. 21(4). 431–436.
2.
Peris, Ketty, Alexander Stratigos, Karl D. Lewis, et al.. (2024). Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. Cancer Medicine. 13(14). e7360–e7360.
3.
Feliciano, Josephine, Yingxin Xu, Ruben G.W. Quek, et al.. (2023). Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer. Frontiers in Oncology. 12. 1081729–1081729.
4.
Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2023). Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3. Cancer. 129(14). 2256–2265.
5.
Solà-Morales, Oriol, Lesley H. Curtis, Deborah Casso, et al.. (2023). Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions. Clinical Pharmacology & Therapeutics. 114(2). 325–355.
6.
Bondarenko, Igor, Ahmet Sezer, Saadettin Kılıçkap, et al.. (2022). 112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology. 33. S84–S85.
7.
Ge, Wenzhen, Ning Wu, Jessica J. Jalbert, et al.. (2022). Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy. Cancer Management and Research. Volume 14. 3191–3202.
8.
Ma, Qiufei, et al.. (2021). Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy. Blood. 138(Supplement 1). 4111–4111.
9.
Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2021). 93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial. Annals of Oncology. 32. S1414–S1414.
10.
Oderda, Gary M., Diana Brixner, Joseph Biskupiak, et al.. (2021). Payer perceptions on the use of patient-reported outcomes in oncology decision making. Journal of Managed Care & Specialty Pharmacy. 28(2). 188–195.
11.
Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535.
12.
Castro, Eva Martínez de, Shona Lang, S Swift, et al.. (2020). Comparing the characteristics of advanced Prostate Cancer (PC) patients with and without DNA Damage Repair mutations (DDRm): A systematic review. European Urology Open Science. 21. S154–S154.
13.
Armstrong, Nigel, Ruben G.W. Quek, Steve Ryder, et al.. (2020). DNA Damage Repair Gene Mutation Testing and Genetic Counseling in Men With/without Prostate Cancer: a Systematic Review. Future Oncology. 17(7). 853–864.
14.
Armstrong, Nigel, Steve Ryder, Carol Forbes, Janine Ross, & Ruben G.W. Quek. (2019). <p>A systematic review of the international prevalence of <em>BRCA </em>mutation in breast cancer</p>. Clinical Epidemiology. Volume 11. 543–561.
15.
Forbes, Carol, Debra Fayter, Shelley de Kock, & Ruben G.W. Quek. (2019). <p>A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of <em>BRCA</em>-mutated breast cancer</p>. Cancer Management and Research. Volume 11. 2321–2337.
16.
Fasching, Peter A., Ruben G.W. Quek, Helen Bhattacharyya, et al.. (2019). Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. Annals of Oncology. 30. iii49–iii49.
17.
Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763.
18.
Wong, Nathan D., Yanglu Zhao, Ruben G.W. Quek, et al.. (2017). Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. Journal of clinical lipidology. 11(5). 1223–1233.
19.
Quek, Ruben G.W., Guillermo Villa, Shravanthi R. Gandra, et al.. (2016). A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. PharmacoEconomics. 35(3). 297–318.
20.
Forbes, Carol, Ruben G.W. Quek, Sohan Deshpande, et al.. (2016). Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review. Current Medical Research and Opinion. 32(6). 1143–1150.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter Barrett‐Lee Breakdown of academic impact, for papers by Erica L. Mayer Breakdown of academic impact, for papers by José Bines Breakdown of academic impact, for papers by Marc Debled Breakdown of academic impact, for papers by Wenting Wu Breakdown of academic impact, for papers by Agustí Barnadas Breakdown of academic impact, for papers by Shannon N. Westin Breakdown of academic impact, for papers by T. Delozier Breakdown of academic impact, for papers by Alistair Ring Breakdown of academic impact, for papers by Masashi Ando